Kanishk Mehta1*, Priti Agarwal2 and Swati Jain3
1Associate Professor, Department of Otorhinolaryngology and Head Neck Surgery, American International Institute of Medical Sciences, Udaipur, Rajasthan, India
2Professor and Head, Department of Pathology, American International Institute of Medical Sciences, Udaipur, Rajasthan, India
3Assistant Professor, Department of Ophthalmology, American International Institute of Medical Sciences, Udaipur, Rajasthan, India
*Corresponding Author: Kanishk Mehta, Associate Professor, Department of Otorhinolaryngology and Head Neck Surgery, American International Institute of Medical Sciences, Udaipur, Rajasthan, India.
Received: May 24, 2021; Published: June 10, 2021
Patients with Coronavirus disease (COVID-19) are commonly treated with broad spectrum antibiotics, glucocorticoids and/or immune modulators. This has led to development/exacerbation of opportunistic fungal infections. Mucormycosis is one such disease that complicates the course of severe COVID-19. Here we present a study of 15 patients and their epidemiology who were diagnosed with Covid19 Associated Mucormycosis (CAM) at our institute - the highest number of cases in literature.
Keywords: Mucormycosis; COVID19; Immunosuppression
Citation: Kanishk Mehta., et al. “Covid 19 Associated Mucormycosis: An Epidemic".Acta Scientific Otolaryngology 3.7 (2020): 27-31.
Copyright: © 2020 Kanishk Mehta., et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.